ERIDAX Trademark

Trademark Overview

On Thursday, July 24, 2003, a trademark application was filed for ERIDAX with the United States Patent and Trademark Office. The USPTO has given the ERIDAX trademark a serial number of 78278620. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 10, 2008. This trademark is owned by Vicuron Pharmaceuticals Inc.. The ERIDAX trademark is filed in the Pharmaceutical Products category with the following description:

PHARMACEUTICALS AND PHARMACEUTICAL AND BIOLOGICAL FORMULATIONS, NAMELY, ANTI-INFECTIVE AGENTS FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS

General Information

Serial Number78278620
Word MarkERIDAX
Filing DateThursday, July 24, 2003
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 10, 2008
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 19, 2005

Trademark Statements

Goods and ServicesPHARMACEUTICALS AND PHARMACEUTICAL AND BIOLOGICAL FORMULATIONS, NAMELY, ANTI-INFECTIVE AGENTS FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 6, 2003
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOSCIENT PHARMACEUTICALS CORPORATION
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressWALTHAM, MA 02451
Party NameVicuron Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKing of Prussia, PA 19406
Party NameVicuron Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKing of Prussia, PA 19406

Trademark Events

Event DateEvent Description
Monday, November 10, 2008ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, November 10, 2008ABANDONMENT - NO USE STATEMENT FILED
Friday, April 11, 2008EXTENSION 5 GRANTED
Friday, April 11, 2008EXTENSION 5 FILED
Friday, April 11, 2008TEAS EXTENSION RECEIVED
Wednesday, February 6, 2008ASSIGNED TO EXAMINER
Tuesday, November 13, 2007ASSIGNED TO EXAMINER
Wednesday, October 17, 2007EXTENSION 4 GRANTED
Wednesday, October 10, 2007EXTENSION 4 FILED
Wednesday, October 10, 2007TEAS EXTENSION RECEIVED
Monday, July 23, 2007EXTENSION 3 GRANTED
Tuesday, April 10, 2007EXTENSION 3 FILED
Monday, April 30, 2007ASSIGNED TO EXAMINER
Tuesday, April 10, 2007TEAS EXTENSION RECEIVED
Wednesday, January 3, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 15, 2006EXTENSION 2 GRANTED
Tuesday, October 10, 2006EXTENSION 2 FILED
Tuesday, October 10, 2006TEAS EXTENSION RECEIVED
Thursday, April 6, 2006EXTENSION 1 GRANTED
Wednesday, March 22, 2006EXTENSION 1 FILED
Wednesday, March 22, 2006TEAS EXTENSION RECEIVED
Tuesday, October 11, 2005NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 19, 2005PUBLISHED FOR OPPOSITION
Wednesday, June 29, 2005NOTICE OF PUBLICATION
Tuesday, April 12, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, April 6, 2005ASSIGNED TO LIE
Wednesday, March 30, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 9, 2005AMENDMENT FROM APPLICANT ENTERED
Tuesday, February 22, 2005CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 22, 2005PAPER RECEIVED
Saturday, August 21, 2004FINAL REFUSAL E-MAILED
Tuesday, August 17, 2004AMENDMENT FROM APPLICANT ENTERED
Monday, August 9, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 9, 2004PAPER RECEIVED
Sunday, February 8, 2004NON-FINAL ACTION E-MAILED
Friday, January 30, 2004ASSIGNED TO EXAMINER

Related Keywords

eridax treatment agents prevention bacterial infections infective anti pharmaceutical biological formulations